GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation.

GALNT6 通过自噬和癌症相关成纤维细胞活化驱动肝细胞癌对乐伐替尼产生耐药性。